CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma , Inc., an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, today announced that Kenneth Pienta, M.D., will serve as acting Chief Medical Officer
CAMBRIDGE, Mass. , June 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that
Initiation of First-in-Human Phase 1 Clinical Trial for Monotherapy Dose Escalation Earns $2.5 Million Milestone for IND Acceptance from Partner LG Chem Life Sciences CAMBRIDGE, Mass. , May 16, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ: CUE), an innovative clinical stage immunotherapy
Completed enrollment of patient expansion cohort of 20 patients at the RP2D of 4 mg/kg in combination with KEYTRUDA ® (pembrolizumab) in first line (1L) refractory/metastatic HPV+ Head and Neck Cancer patients Data to date from CUE-101 in combination with pembrolizumab demonstrates more than
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cue Biopharma™, Inc., (NASDAQ: CUE) an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune
Change represents evolving board capabilities as Cue Biopharma enters next stage of its corporate development CAMBRIDGE, Mass. , Oct. 09, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE) a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to
CAMBRIDGE, Mass. , Dec. 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today the
Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs CAMBRIDGE, Mass. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.
CAMBRIDGE, MA, Dec 5, 2017 – Cue Biopharma™, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, today announced the appointment of Colin Sandercock as Senior Vice President and General Counsel.
Dr. Suri’s appointment to senior leadership team adds depth and expertise in immunology and translational studies CAMBRIDGE, Mass. , April 25, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc. (NASDAQ:CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics